Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Understand portfolio volatility for bonds versus index funds in retirement and how it affects withdrawal strategies and peace of mind.
23,485 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Anthropic and Airbnb are placing big bets on New York City, expanding footprints and hiring aggressively while critic...
Archer Aviation is progressing toward certification and scale, but the road to profitability remains long. This artic...
Jim Cramer argues that the MAG 7 must be analyzed separately, not as a single basket, outlining five core reasons eac...
Public chatter around a high-profile settlement can echo into your finances. This article breaks down the money moves...
With Senate leadership sidelined, key defense funding plans face delay as Iran tensions intensify and midterms loom. ...
Ripple, Coinbase, and Circle have joined the Linux Foundation's x402 Foundation as premier members, signaling a push ...
Investors are buzzing about The Metals Company as a potential new source of critical minerals. This article weighs th...
JPMorgan Chase's CEO says the public frustration with wealth concentration is real, and calls for policy and corporat...
Anthropic’s rumored trillion-dollar IPO has investors buzzing, yet a wave of caution surrounds the offering amid valu...
Strategy's Phong Le anchors the firm's crypto stance to a debt-risk threshold at $8K–$10K, underscoring balance-sheet...
Mid-year, Figma faces a volatile path as investors weigh AI-led growth against high valuation. A refreshed price pred...